1. "It is anticipated that additional partnership will be secured for the company’s xB3 drug delivery platform in 2019 and 2020."

2. "Due to a decline in market conditions subsequent to the announcement, the Company has not completed the private placement. However, the Company continues to pursue alternate sources of capital financing including a non-convertible instrument and a non-brokered private placement with existing shareholders, amongst other financing initiatives." 

3. "In parallel, the Company is actively pursuing multiple technology licensing transactions which may yield near term cash inflows from upfront payments."

4. "Additionally, the Company has achieved forward momentum with one of its current licensing transactions, which is positioned to yield near term cash inflows

I dont know if its the direct impact of DRDR in the MD&A but its pretty clear money is coming in. Their working capital was short 1.2M two months ago. I hope its over 2M since they burn 1M a Q.